416 related articles for article (PubMed ID: 11747595)
1. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity.
Kianmanesh A; Hackett NR; Lee JM; Kikuchi T; Korst RJ; Crystal RG
Hum Gene Ther; 2001 Nov; 12(17):2035-49. PubMed ID: 11747595
[TBL] [Abstract][Full Text] [Related]
2. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
3. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells.
Kikuchi T; Maemondo M; Narumi K; Matsumoto K; Nakamura T; Nukiwa T
Blood; 2002 Dec; 100(12):3950-9. PubMed ID: 12393687
[TBL] [Abstract][Full Text] [Related]
7. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents.
Candido KA; Shimizu K; McLaughlin JC; Kunkel R; Fuller JA; Redman BG; Thomas EK; Nickoloff BJ; Mulé JJ
Cancer Res; 2001 Jan; 61(1):228-36. PubMed ID: 11196166
[TBL] [Abstract][Full Text] [Related]
8. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
9. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth.
Fushimi T; Kojima A; Moore MA; Crystal RG
J Clin Invest; 2000 May; 105(10):1383-93. PubMed ID: 10811846
[TBL] [Abstract][Full Text] [Related]
10. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
Tanaka F; Hashimoto W; Robbins PD; Lotze MT; Tahara H
Gene Ther; 2002 Nov; 9(21):1480-6. PubMed ID: 12378411
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.
Song W; Kong HL; Carpenter H; Torii H; Granstein R; Rafii S; Moore MA; Crystal RG
J Exp Med; 1997 Oct; 186(8):1247-56. PubMed ID: 9334364
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
15. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
[TBL] [Abstract][Full Text] [Related]
16. Induction of leukemia-specific CD8+ cytotoxic T cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-alpha.
Saudemont A; Corm S; Wickham T; Hetuin D; Quesnel B
Mol Ther; 2005 Jun; 11(6):950-9. PubMed ID: 15922966
[TBL] [Abstract][Full Text] [Related]
17. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors.
Tong Y; Song W; Crystal RG
Cancer Res; 2001 Oct; 61(20):7530-5. PubMed ID: 11606390
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
Kikuchi T; Moore MA; Crystal RG
Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A
Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
